Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study (Q37690732)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 February 2014

Language	Label	Description	Also known as
English	Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study	scientific article published on 24 February 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study (English)

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

10

object named as

Linda Chang

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

author name string

Avram Goldberg

1

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Thomas Geppert

2

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Elena Schiopu

3

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Tracy Frech

4

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Vivien Hsu

5

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Robert W Simms

6

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Stanford L Peng

7

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Yihong Yao

8

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Nairouz Elgeioushi

9

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Bing Wang

11

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Stephen Yoo

12

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

publication date

24 February 2014

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Arthritis Research and Therapy

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

16

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

R57

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Immunotherapy of systemic sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

The pathogenesis of systemic sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

Evidence-based management of rapidly progressing systemic sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

Pharmacotherapy of systemic sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

Disease-modifying treatment in systemic sclerosis: current status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

The complexity of managing systemic sclerosis: screening and diagnosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

Type I interferon: potential therapeutic target for psoriasis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

Scleroderma--clinical and pathological advances

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

Systemic and cell type-specific gene expression patterns in scleroderma skin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

The type I interferon receptor: structure, function, and evolution of a family business.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

How cells respond to interferons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 August 2017

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

6 September 2017

Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

14 September 2017

Type I interferon system activation and association with disease manifestations in systemic sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

14 September 2017

Immune Interferon in the Circulation of Patients with Autoimmune Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

23 June 2018

The uncontrolled clinical trial: scientific, ethical, and practical reasons for being

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

1 September 2018

Critical role for constitutive type I interferon signaling in the prevention of cellular transformation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

1 September 2018

Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

1 September 2018

A critical function for type I interferons in cancer immunoediting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

1 September 2018

Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

1 September 2018

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

1 September 2018

Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978926

1 September 2018

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1186%2FAR4492

21 January 2018

Systemic sclerosis prevalence and comorbidities in the US, 2001-2002

1 reference

https://pubmed.ncbi.nlm.nih.gov/24559157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic Sclerosis after Interferon Alphacon-1 Therapy for Hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/24559157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24559157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24559157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica

1 reference

https://pubmed.ncbi.nlm.nih.gov/24559157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24559157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/24559157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/24559157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/24559157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37690732&oldid=2223421103"